Tirzepatide is a medication that's revolutionizing weight loss and diabetes treatment, helping people lose an average of 20-22% of their body weight — more than any other approved weight loss drug. Think of it as a sophisticated messenger that talks to your body in two different languages at once, which is why it works so remarkably well.
When you inject tirzepatide, it mimics two natural hormones your intestines normally release when you eat. Imagine your body has two separate communication channels — GIP and GLP-1 — that control hunger, blood sugar, and fat storage. Most similar medications only activate one channel, but tirzepatide activates both simultaneously, like having a conversation in stereo.
On the GLP-1 side, it tells your brain "you're full" much sooner and keeps food in your stomach longer, so you naturally eat less. It also helps your pancreas release insulin more effectively when your blood sugar rises. Meanwhile, the GIP pathway works behind the scenes in your fat tissue, making your body more sensitive to insulin and better at burning stored fat. When both pathways work together, they create a synergistic effect — like two musicians harmonizing to create something more beautiful than either could alone. This dual action produces dramatically better results than single-pathway medications.
Dosage Information
Typical Dose
2.5-15 mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection
Half-Life
5 days
Notes
Titrated over 20 weeks from 2.5mg to maximum 15mg. Requires medical supervision. Supply shortages have been a significant issue since approval.
Why this matters
Dual GIP/GLP-1 agonist with extended half-life supporting once-weekly injection.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
100
unit mark
Draw 100 units for your 2500mcg dose of Tirzepatide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Tirzepatide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.62
Compound Data
Molecular Formula
C225H348N48O68
Molecular Weight
4813.00 g/mol
IUPAC Name
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
166567236Potential Side Effects
Tirzepatide discussions
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 2.5-15 mg weekly
- Frequency
- Once weekly
- References
- 0 curated + 19 from PubMed
- Clinical Trials
- 39 registered
- Evidence Score
- 0.6 / 100
Frequently Asked Questions about Tirzepatide
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA under the brand name Mounjaro for type 2 diabetes and Zepbound for obesity. It simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing greater weight loss and glycemic control than GLP-1 receptor agonists alone. Phase 3 SURMOUNT trials demonstrated average weight loss of 20-22% of body weight — the greatest ever seen in a pharmaceutical weight management trial — positioning tirzepatide as the most effective approved pharmacological weight loss intervention available.
How does Tirzepatide work?
Tirzepatide is a 39-amino-acid synthetic peptide that acts as an agonist at both GIP receptors and GLP-1 receptors simultaneously. GIP receptor activation in adipose tissue enhances insulin sensitivity and lipid metabolism, while GLP-1 receptor activation provides the incretin, appetite-suppressing, and gastric emptying effects established for that receptor class. The dual agonism appears synergistic — GIP potentiates GLP-1 receptor signaling and adds complementary metabolic effects that single GLP-1 agonists cannot achieve. In the brain, combined GIP and GLP-1 receptor activation produces stronger appetite suppression than either alone. The result is superior weight loss efficacy compared to selective GLP-1 agonists, with comparable or better tolerability.
What is the recommended dosage for Tirzepatide?
The typical dose is 2.5-15 mg weekly. Once weekly. Administration: Subcutaneous injection. Titrated over 20 weeks from 2.5mg to maximum 15mg. Requires medical supervision. Supply shortages have been a significant issue since approval.
What are the side effects of Tirzepatide?
Nausea (very common during dose escalation). Diarrhea (common). Vomiting (common). Constipation (common). Reduced appetite (pronounced). Thyroid C-cell tumor risk (black box warning). Pancreatitis (rare)
What is the Tirzepatide cycle protocol?
Tirzepatide is typically cycled ongoing. Weekly subcutaneous injection, titrated over 20 weeks
Questions reflect common community inquiries. This is not medical advice.